Investing primarily in equity securities of health care and health care-related companies located throughout the world
Employing rigorous bottom-up research to identify companies with long-term growth potential in various market conditions by focusing on those with a history of high returns on invested capital, strong free cash flows and attractive valuations
Emphasizing companies that are expected to attract health care spending, generally through the introduction of new treatments and therapies or by offering customers cost reduction opportunities
The Portfolio uses the benchmark shown for comparison purposes only. The Portfolio is actively managed and the Investment Manager is not constrained by its benchmark when implementing the Portfolio’s investment strategy.
| Morningstar Ratings as of 08/04/2025 | ||||
|---|---|---|---|---|
| Category: Sector Equity Healthcare | ||||
| Overall | 3 Year | 5 Year | 10 Year | |
| Rating | ||||
| Investments in Category | 719 Funds | 719 Funds | 483 Funds | 244 Funds |
Source: Morningstar
"Overall Morningstar Rating is a copyright of Morningstar, Inc., 2024. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.
Morningstar rates funds from one star to five stars based on how well the funds have performed (after adjusting for risk) in comparison to similar funds. Within each Morningstar Category, the top 10% of funds receive five stars, the next 22.5% four stars, the middle 35% three stars, the next 22.5% two stars, and the bottom 10% receive one star. Funds are rated for up to three time periods, in three years, five years, and ten years, and these ratings are combined to produce an overall rating. Funds with less than three years of history are not rated. Ratings are objective, based entirely on a mathematical evaluation of past performance. They are a useful tool for identifying funds worthy of further research, but should not be considered buy or sell recommendations."
Ongoing charges include fees and certain expenses of the Portfolio as of the most recent KIID, and may be subject to a cap which is reflected above if applicable.
Holdings are subject to change without notice.
These and other risks are described in the Fund’s prospectus
Investment returns and principal value of the Fund will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than their original cost. Some of the principal risks of investing in the Fund include:
